EWEmily Chu Lee Wong

Emily Chu Lee Wong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Emily Chu Lee Wong has a total of 131 co-authors. Here are the top co-authors by number of shared publications:

  • Neeraj Narula

    Division of Gastroenterology, Department of Medicine, Farncombe Family Digestive Health Research Institute, McMaster University, Hamilton, Ontario, Canada

    33 shared publications
  • Walter Reinisch

    Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria

    17 shared publications
  • Vipul Jairath

    Division of Gastroenterology, Department of Medicine, Western University , London, ON

    15 shared publications
  • John K Marshall

    Division of Gastroenterology, Department of Medicine and Farncombe Family Digestive Health Research Institute, McMaster University , Hamilton, ON

    14 shared publications
  • Walter Reinisch

    Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Medical University of Vienna, Währinger Gürtel 18-20, Vienna, Austria

    11 shared publications
  • John K. Marshall

    Department of Medicine (Division of Gastroenterology) and Farncombe Family Digestive Health Research Institute; McMaster University, Hamilton ON, Canada

    10 shared publications

Latest Publications

  • Open Access

    Serum MMP-10 levels predict incident inflammatory bowel disease: an observational analysis from the PURE study

    by Emily C L Wong, Walter Reinisch, Paul Moayyedi, Sumathy Rangarajan, Philip Joseph, Paul Poirier, Scott Lear, Maria Luz Diaz, Roya Kelishadi, Alvaro Avezum, et al.

    Background and aims: The incidence of inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), is rising, particularly in middle-income countries. This study aims to identify biomarkers that predict the onset of IBD in a globally recruited population. Methods: Data from participants enrolled in the biomarker substudy of the Prospective Urban Rural Epidemiology (PURE) study were analyzed (discovery cohort). The primary outcome of interest was the development of incident IBD. Secondary outcomes were CD and UC. Protein concentration was measured using O-link® immuno-assays. Discovery analyses consisted of logistic regression models to evaluate the relationship between biomarker concentrations and risk of IBD. A separate analysis was conducted to validate biomarkers identified from the discovery cohort. Statistical significance was defined using a Bonferroni-corrected P < 1.6 × 10−5 for all analyses. Results: A total of 1011 biomarkers were assessed in the discovery cohort across 11 019 participants with n = 91 incident IBD cases. In the discovery analysis, elevated levels of matrix metalloproteinase-10 (MMP-10) were significantly associated with a future diagnosis of IBD (adjusted odds ratio [aOR] per SD: 1.75, 95% confidence interval [CI]: 1.40-2.18, P = 7.6 × 10−7). Results were consistent in direction for development of both UC and CD. In the validation analysis, MMP-10 remained significant for the outcome of IBD (aOR per SD: 2.41 [95% CI: 1.61-4.58], P = 5.2 × 10−6). Conclusions: These findings suggest MMP-10 is a relevant biomarker in the general global population for prediction of clinical IBD, and further work should investigate its role in early detection and prevention strategies.

  • Open Access

    Efficacy and safety of ulcerative colitis therapies do not differ by age: A post hoc analysis of randomized controlled trials

    by Emily C L Wong, John K Marshall, Christopher Ma, Vipul Jairath, Walter Reinisch, Neeraj Narula

    Background: Older adults with ulcerative colitis (UC) are often undertreated with advanced therapies due to safety concerns. We evaluated whether outcomes differ by age in randomized trials. Methods: Post hoc analysis of 2841 participants from 13 UC induction trials of biologics and JAK inhibitors compared efficacy (patient-reported outcomes 2 response/remission, clinical remission, endoscopic improvement) and safety between patients ≥60 years of age vs <60 years of age. Results: Efficacy and safety outcomes were similar across age groups, with minor therapy-specific variation. Hospitalization was numerically higher in older adults. Conclusions: Advanced therapies show comparable efficacy and safety in UC regardless of age.

  • Infliximab and Upadacitinib Demonstrate Superior Early Onset of Efficacy in Biologic-Naïve Ulcerative Colitis With Severe Endoscopic Disease

    by Emily C. L. Wong, Vipul Jairath, Parambir S. Dulai, John K. Marshall, Christopher Ma, Walter Reinisch, Neeraj Narula

    INTRODUCTION: Rapid symptom control is critical in managing ulcerative colitis (UC), especially in patients with severe disease. Although multiple advanced therapies are approved for moderate to severe UC, data comparing their speed of onset are limited. We compared the onset and induction efficacy of advanced therapies for UC among biologic-naïve patients with severe endoscopic disease (Mayo endoscopic score [MES] of 3) and explored differential responses in patients with moderate (MES 2) vs severe endoscopic disease. METHODS: This was a post hoc analysis using individual participant-level data from 11 randomized controlled trials. Biologic-naïve patients with MES 3 disease receiving standard induction regimens of infliximab, adalimumab, golimumab, vedolizumab, ustekinumab, mirikizumab, tofacitinib, or upadacitinib were included. The primary outcome was early PRO-2 response, defined as ≥50% reduction in stool frequency and rectal bleeding scores at 2 weeks postbaseline. Secondary outcomes included postinduction clinical remission and PRO-2 remission. Logistic regression models adjusted for baseline covariates were used. RESULTS: A total of 1,781 biologic-naïve patients with MES 3 disease were included. Infliximab (35.1%) and upadacitinib (32.4%) demonstrated the highest early PRO-2 response rates. Compared with placebo, the highest odds of response were observed with upadacitinib (adjusted odds ratio: 6.38 [95% CI: 2.11–19.23], P = 0.001) and infliximab (adjusted odds ratio 4.49 [95% CI: 2.05–9.85], P < 0.001). At postinduction, infliximab (72.2%) and upadacitinib (59.5%) again demonstrated superior PRO-2 response rates. In comparison to MES 2 patients, those with MES 3 had reduced odds of early and postinduction response for several therapies, particularly ustekinumab, tofacitinib, vedolizumab, and mirikizumab. DISCUSSION: Among biologic-naïve UC patients with severe endoscopic disease, infliximab and upadacitinib had the highest rates of week 2 and postinduction PRO-2 response. Baseline disease activity may help to better inform treatment choices.


  • Open Access

    Week 12 Reduction in Modified Multiplier of the Simple Endoscopic Score for Crohn’s Disease is Predictive of Delayed Response to Upadacitinib in Crohn’s Disease

    by Emily C.L. Wong, Parambir S. Dulai, John K. Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

  • Open Access

    Serum and Histologic Eosinophilia as a Predictive Biomarker of Response to Mirikizumab in Ulcerative Colitis

    by Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

    Introduction: Eosinophils may contribute to ulcerative colitis (UC) pathogenesis through inflammation and epithelial injury. Mirikizumab, a selective IL-23 inhibitor, has shown efficacy in moderate-to-severe UC. However, the relationship between eosinophils and treatment outcomes with IL-23 inhibition remains unclear. Objective: This post-hoc analysis of the LUCENT-1 trial evaluated trends in serum and histologic eosinophils as biomarkers for early response to mirikizumab induction therapy in UC. Design: Data from LUCENT-1 (NCT03518086) were analyzed to assess serum eosinophil counts and histologic eosinophil presence at baseline and week 12. Clinical response, remission, and endoscopic improvement were defined by modified Mayo score criteria. Logistic regression models, adjusted for factors including steroid use, prior biologic failure, disease severity, and albumin levels, assessed associations between baseline eosinophil levels and treatment outcomes. Results: Among 928 participants, 66.6% achieved clinical response. Responders had higher baseline serum eosinophils (0.23 × 109/L vs 0.19 × 109/L, P = .001) and showed greater reductions at week 12. Elevated baseline eosinophils (≥0.57 × 109/L) were associated with higher rates of clinical response (80% vs 65.7%, aOR: 2.31, P = .013), remission (33.3% vs 25.1%, aOR: 1.91, P = .044), and endoscopic improvement (46.7% vs 33.8%, aOR: 2.33, P = .003). Reductions in histologic eosinophils were also linked to improved outcomes, especially in those with moderate/marked baseline presence. Conclusions and Relevance: Baseline eosinophil levels may predict response to mirikizumab and guide early treatment decisions. These findings support a potential role for eosinophils as biomarkers in UC management.

  • Open Access

    Anti-TNF Therapies Promote a Proximal-to-Distal Healing Pattern in Moderate-to-Severe Ulcerative Colitis

    by Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

    Background: Ulcerative colitis (UC) is a chronic inflammatory disease of the colonic mucosa, extending proximally from the rectum. However, the segmental pattern of healing in UC remains unclear. Endoscopic improvement (EI), a key therapeutic endpoint, is typically assessed using the Mayo endoscopic score (MES), which scores the worst affected area and may miss partial/segmental healing. This study evaluates healing patterns in UC and compares conventional MES with a 3-segment MES approach for detecting treatment effects in clinical trials. Methods: A post hoc analysis of HIBISCUS I/II and GARDENIA trials was conducted in UC patients with moderate-to-severe disease (MES >2 up to the descending colon). The primary outcome was the proportion of anti-tumor necrosis factor–treated participants achieving MES ≤1 in the descending colon, sigmoid colon, and rectum at week 10. Secondary outcomes included conventionally measured EI, segmental MES improvements, clinical response, and Patient-Reported Outcome 2 (PRO2) normalization. Outcomes were compared between adalimumab, infliximab, and placebo groups. Results: Among 300 participants, 217 received infliximab or adalimumab, while 83 received placebo. Healing followed a proximal-to-distal pattern, with the highest EI in the descending colon and the lowest in the rectum. Infliximab-treated patients continued this trend at week 54. Anti-tumor necrosis factor therapy significantly improved EI vs placebo (42.9% vs 19.3%; P < .001). No segmental MES approach outperformed conventional MES for detecting treatment effects. Combined endpoints (MES ≤1 + PRO2 normalization) better captured therapeutic benefits than PRO2 alone (28.6% vs 13.3%; P = .006). Conclusions: UC healing follows a proximal-to-distal pattern. Conventional MES remains superior for detecting treatment effects over segmental MES. Further studies should explore alternative endoscopic scoring methodologies.

  • Ultraprocessed Grains and Risk of Inflammatory Bowel Disease: Results From the Prospective Urban Rural Epidemiology Study

    by Neeraj Narula, Emily C.L. Wong, Andrew Mente, Sumathy Rangarajan, Xinyue Lang, Qi Li, Mengxi Chen, Indu Mohan, Nafiza Mat-Nasir, Maria Luz Diaz, et al.

    INTRODUCTION: Ultraprocessed grains, commonly consumed in Western diets, undergo refining processes that often remove beneficial components and include additives to enhance taste, texture, or durability, potentially influencing gastrointestinal health. This study examines the association between ultraprocessed grain consumption and the risk of developing inflammatory bowel disease (IBD) using data from the Prospective Urban Rural Epidemiology (PURE) study. METHODS: This analysis included 124,590 participants from 21 countries who had dietary data available in the PURE study. Dietary intake was assessed through validated food frequency questionnaires, and ultraprocessed grain intake was categorized into 3 levels. The primary outcome was the development of IBD, including Crohn's disease (CD) and ulcerative colitis (UC). Multivariate Cox proportional hazard models were used to calculate hazard ratios (HRs), adjusting for confounders including age, sex, smoking status, eating habits, and physical activity. RESULTS: Among 124,590 participants, higher ultraprocessed grain intake was associated with increased IBD risk. Participants consuming ≥19 g/d of ultraprocessed grains had a higher risk of developing IBD compared with those consuming P trend = 0.0003) after multivariate adjustment. Fresh bread and rice consumption were associated with lower IBD risk. Participants with greater ultraprocessed food intake (≥5 servings per day) were linked to a higher risk of developing IBD compared with those consuming P trend < 0.0001). DISCUSSION: Higher intake of ultraprocessed grains is associated with significantly increased risk of developing IBD. A healthy eating pattern should minimize consumption of ultraprocessed grains. Further studies should be performed to understand which components of ultraprocessed grains may be detrimental for health.


  • Open Access

    Comparative Predictive Utility of MM-SES-CD and SES-CD for Week 52 Endoscopic Remission in the Ileum and Colon in Crohn’s Disease

    by Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

    Background: The Simple Endoscopic Score for Crohn’s disease (SES-CD) and Modified Multiplier of the SES-CD (MM-SES-CD) are endoscopic scoring systems used to assess disease severity and response to therapy in CD. This study evaluates their utility at baseline in predicting endoscopic remission (ER) of the ileum and colon at week 52. Methods: This post-hoc analysis of 4 clinical trials (CT-P13, UNITI, EXTEND, and SEAVUE) compared baseline scores and ER outcomes at week 52 using the SES-CD and MM-SES-CD. The area under the receiver operating characteristic curve (AUC) for each scoring system’s ability to predict week 52 ER defined by various thresholds was compared. Results: A total of 667 patients were included in this analysis. At baseline, the median SES-CD score was 8.5 (IQR 5.0–15.7), and the median MM-SES-CD score was 34.8 (IQR 27.5–50.0). MM-SES-CD demonstrated consistently higher AUC values compared to SES-CD across most endpoints in ileal and colonic disease involvement. Among 519 patients with any disease in the ileum, baseline MM-SES-CD demonstrated significantly better predictive accuracy than SES-CD for week 52 SES-CD < 3 [AUC 0.75 (95% CI: 0.71–0.80) vs. 0.64 (95% CI: 0.59–0.70), P = .031]. Similar findings were observed for other definitions of ER. Among 552 participants with colonic disease involvement, baseline MM-SES-CD also demonstrated significantly greater accuracy for predicting week 52 SES-CD < 3 [AUC 0.78 (95% CI: 0.73–0.82) vs. 0.62 (95% CI: 0.57–0.66), P = .002], with similar findings across other definitions of ER assessed. Similar trends were observed across isolated ileal, ileocolonic, and isolated colonic disease. Conclusion: The baseline MM-SES-CD demonstrated superior predictive ability for week 52 ER compared to SES-CD across the ileum and colon. These findings support its utility in clinical trials and in routine practice for predicting long-term treatment response.


  • A Review of the Modified Multiplier of Simple Endoscopic Score for Crohn's Disease and How to Use It in Clinical Trials and Practice

    by Peter W. Huan, Akash Mehta, Emily C.L. Wong, Parambir S. Dulai, John K. Marshall, Walter Reinisch, Neeraj Narula

    Endoscopic evaluation is valuable in the diagnosis, assessment, and management of Crohn's disease (CD). The Simple Endoscopic Score for CD (SES-CD) was created using a uniform, linear scoring scale of 0–3 for each of its 4 parameters at 5 anatomic locations and was designed to accurately indicate disease severity rather than predicting disease progression. There is evidence to suggest that all disease segments and parameters of the SES-CD do not have equal prognostic value for likelihood of achieving endoscopic remission. The Modified Multiplier SES-CD, developed by multivariable logistic regression modeling, weighs the individual parameters of the SES-CD including disease distribution based on their prognostic values for achieving endoscopic remission. The objective of this qualitative review is to provide guidance to clinicians and clinical trialists for how to use and interpret the Modified Multiplier SES-CD.


  • Open Access

    Improvement in serum eosinophilia is observed in clinical responders to ustekinumab but not adalimumab in inflammatory bowel disease

    by Emily C L Wong, Parambir S Dulai, John K Marshall, Vipul Jairath, Walter Reinisch, Neeraj Narula

    Introduction: In inflammatory bowel disease (IBD), the number of eosinophils increases in the lamina propria of the intestinal tract, but their specific patho-mechanistic role remains unclear. Elevated blood eosinophil counts in active IBD suggest their potential as biomarkers for predicting response to biological therapies. This study evaluates blood eosinophil count trends and their predictive value for clinical response and endoscopic improvement in patients with IBD receiving ustekinumab or adalimumab induction therapy. Methods: Participant-level data from phase 3 and 4 clinical trials (UNIFI, SEAVUE, VARSITY) evaluating ustekinumab and adalimumab for moderate–severe Crohn’s disease (CD) and ulcerative colitis (UC) were used. The primary outcome was clinical response, defined by reductions in disease activity scores. Eosinophil counts were compared between responders and non-responders at multiple time points using t-tests. Logistic regression assessed the odds of achieving a clinical response based on baseline eosinophil counts. Results: Among patients treated with ustekinumab for UC, responders had significantly higher baseline eosinophil counts compared to non-responders (0.21 × 109/L vs 0.18 × 109/L, P = .042). By week 8, responders showed a greater absolute (−0.07 × 109/L vs −0.01 × 109/L, P < .001) and percent decline (−33.33% vs −5.55%, P = .027) in eosinophil counts. In CD, ustekinumab responders also had higher baseline eosinophil counts and showed significant reductions by week 8. However, no significant differences in eosinophil counts were observed among CD patients treated with adalimumab or UC patients treated with vedolizumab. Conclusion: Eosinophil reduction was identified as a marker for early response to ustekinumab in both UC and CD, but not adalimumab. No difference was observed among UC patients treated with vedolizumab either. Targeting the IL-12/IL-23 pathway may be more effective in managing eosinophil-associated inflammation in IBD.